|
Gene: METTL3 |
Gene summary for METTL3 |
Gene summary. |
Gene information | Species | Human | Gene symbol | METTL3 | Gene ID | 56339 |
Gene name | methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit | |
Gene Alias | IME4 | |
Cytomap | 14q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q86U44 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56339 | METTL3 | LZE2T | Human | Esophagus | ESCC | 2.41e-02 | 3.14e-01 | 0.082 |
56339 | METTL3 | LZE4T | Human | Esophagus | ESCC | 1.37e-04 | 1.21e-01 | 0.0811 |
56339 | METTL3 | LZE7T | Human | Esophagus | ESCC | 4.34e-02 | 1.82e-01 | 0.0667 |
56339 | METTL3 | LZE20T | Human | Esophagus | ESCC | 2.47e-03 | 9.59e-02 | 0.0662 |
56339 | METTL3 | LZE24T | Human | Esophagus | ESCC | 1.84e-13 | 2.59e-01 | 0.0596 |
56339 | METTL3 | P1T-E | Human | Esophagus | ESCC | 6.42e-04 | 1.76e-01 | 0.0875 |
56339 | METTL3 | P2T-E | Human | Esophagus | ESCC | 3.63e-15 | 1.57e-01 | 0.1177 |
56339 | METTL3 | P4T-E | Human | Esophagus | ESCC | 5.81e-16 | 2.79e-01 | 0.1323 |
56339 | METTL3 | P5T-E | Human | Esophagus | ESCC | 3.87e-07 | 1.11e-01 | 0.1327 |
56339 | METTL3 | P8T-E | Human | Esophagus | ESCC | 7.83e-26 | 2.33e-01 | 0.0889 |
56339 | METTL3 | P9T-E | Human | Esophagus | ESCC | 5.90e-07 | 1.58e-01 | 0.1131 |
56339 | METTL3 | P10T-E | Human | Esophagus | ESCC | 2.08e-31 | 3.88e-01 | 0.116 |
56339 | METTL3 | P11T-E | Human | Esophagus | ESCC | 6.72e-05 | 3.01e-01 | 0.1426 |
56339 | METTL3 | P12T-E | Human | Esophagus | ESCC | 1.92e-27 | 5.09e-01 | 0.1122 |
56339 | METTL3 | P15T-E | Human | Esophagus | ESCC | 3.79e-27 | 3.38e-01 | 0.1149 |
56339 | METTL3 | P16T-E | Human | Esophagus | ESCC | 1.25e-17 | 1.77e-01 | 0.1153 |
56339 | METTL3 | P17T-E | Human | Esophagus | ESCC | 6.20e-03 | 1.98e-01 | 0.1278 |
56339 | METTL3 | P20T-E | Human | Esophagus | ESCC | 2.70e-11 | 1.13e-01 | 0.1124 |
56339 | METTL3 | P21T-E | Human | Esophagus | ESCC | 1.66e-12 | 1.10e-01 | 0.1617 |
56339 | METTL3 | P22T-E | Human | Esophagus | ESCC | 8.38e-19 | 2.09e-01 | 0.1236 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00342495 | Oral cavity | OSCC | negative regulation of cellular amide metabolic process | 130/7305 | 273/18723 | 2.20e-03 | 1.00e-02 | 130 |
GO:00322591 | Oral cavity | OSCC | methylation | 168/7305 | 364/18723 | 3.03e-03 | 1.31e-02 | 168 |
GO:20007364 | Oral cavity | OSCC | regulation of stem cell differentiation | 33/7305 | 58/18723 | 4.32e-03 | 1.75e-02 | 33 |
GO:00075493 | Oral cavity | OSCC | dosage compensation | 13/7305 | 18/18723 | 4.45e-03 | 1.79e-02 | 13 |
GO:00310507 | Oral cavity | OSCC | dsRNA processing | 31/7305 | 54/18723 | 4.66e-03 | 1.87e-02 | 31 |
GO:00709187 | Oral cavity | OSCC | production of small RNA involved in gene silencing by RNA | 31/7305 | 54/18723 | 4.66e-03 | 1.87e-02 | 31 |
GO:00351968 | Oral cavity | OSCC | production of miRNAs involved in gene silencing by miRNA | 30/7305 | 52/18723 | 4.84e-03 | 1.92e-02 | 30 |
GO:00022445 | Oral cavity | OSCC | hematopoietic progenitor cell differentiation | 57/7305 | 114/18723 | 1.09e-02 | 3.71e-02 | 57 |
GO:00456194 | Oral cavity | OSCC | regulation of lymphocyte differentiation | 83/7305 | 174/18723 | 1.18e-02 | 4.00e-02 | 83 |
GO:00171485 | Oral cavity | OSCC | negative regulation of translation | 113/7305 | 245/18723 | 1.34e-02 | 4.45e-02 | 113 |
GO:00224086 | Oral cavity | OSCC | negative regulation of cell-cell adhesion | 92/7305 | 196/18723 | 1.41e-02 | 4.64e-02 | 92 |
GO:00488637 | Oral cavity | OSCC | stem cell differentiation | 96/7305 | 206/18723 | 1.55e-02 | 4.99e-02 | 96 |
GO:00800091 | Oral cavity | OSCC | mRNA methylation | 11/7305 | 16/18723 | 1.56e-02 | 4.99e-02 | 11 |
GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
GO:003447014 | Oral cavity | LP | ncRNA processing | 184/4623 | 395/18723 | 1.20e-21 | 3.12e-19 | 184 |
GO:000641319 | Oral cavity | LP | translational initiation | 75/4623 | 118/18723 | 3.96e-19 | 7.52e-17 | 75 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
METTL3 | SNV | Missense_Mutation | c.1177N>G | p.Met393Val | p.M393V | Q86U44 | protein_coding | deleterious(0) | possibly_damaging(0.78) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
METTL3 | SNV | Missense_Mutation | c.1522N>G | p.Arg508Gly | p.R508G | Q86U44 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B6-A1KF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
METTL3 | deletion | Frame_Shift_Del | novel | c.1626delN | p.Asn543ThrfsTer15 | p.N543Tfs*15 | Q86U44 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
METTL3 | SNV | Missense_Mutation | c.1495N>A | p.Asp499Asn | p.D499N | Q86U44 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
METTL3 | SNV | Missense_Mutation | c.656N>T | p.Ser219Leu | p.S219L | Q86U44 | protein_coding | tolerated(0.1) | benign(0.021) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
METTL3 | SNV | Missense_Mutation | novel | c.52N>G | p.Leu18Val | p.L18V | Q86U44 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
METTL3 | SNV | Missense_Mutation | novel | c.341N>G | p.Asp114Gly | p.D114G | Q86U44 | protein_coding | tolerated(0.37) | benign(0) | TCGA-A6-3807-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Ancillary | leucovorin | SD |
METTL3 | SNV | Missense_Mutation | c.157C>T | p.Pro53Ser | p.P53S | Q86U44 | protein_coding | tolerated(0.4) | benign(0.019) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
METTL3 | SNV | Missense_Mutation | c.1243N>T | p.Arg415Cys | p.R415C | Q86U44 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
METTL3 | SNV | Missense_Mutation | c.1217A>G | p.Tyr406Cys | p.Y406C | Q86U44 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3989-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |